7:27 am GlaxoSmithKline withdraws its application to the EMA for a variation to the Marketing Authorisation for Votrient (pazopanib)
View todays social media effects on GSK
View the latest stocks trending across Twitter. Click to view dashboard
See who GlaxoSmithKline is hiring next, click here to view
